UNBX (Unity Biotechnology) Ending Cash Position: $8.90 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Unity Biotechnology Ending Cash Position?

Unity Biotechnology UNBX Ending Cash Position is $8.90 Mil as of Mar. 2025.

Unity Biotechnology's Ending Cash Position for the quarter that ended in Mar. 2025 was $8.90 Mil.

Unity Biotechnology's quarterly Ending Cash Position declined from Sep. 2024 ($9.79 Mil) to Dec. 2024 ($8.48 Mil) but then increased from Dec. 2024 ($8.48 Mil) to Mar. 2025 ($8.90 Mil).

Unity Biotechnology's annual Ending Cash Position increased from Dec. 2022 ($13.63 Mil) to Dec. 2023 ($20.70 Mil) but then declined from Dec. 2023 ($20.70 Mil) to Dec. 2024 ($8.48 Mil).

Unity Biotechnology Ending Cash Position Related Terms

Unity Biotechnology Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Ending Cash Position Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 19.25 34.35 13.63 20.70 8.48

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.33 8.48 9.79 8.48 8.90

Unity Biotechnology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Unity Biotechnology's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=20.699+-12.223
=8.48

Unity Biotechnology's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.476+0.419
=8.90

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $8.90 Mil mean?
Unity Biotechnology (UNBX) has a Ending Cash Position of $8.90 Mil as of Mar. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Unity Biotechnology and its competitors.
Is Unity Biotechnology's Ending Cash Position too high?
Unity Biotechnology's current Ending Cash Position is $8.90 Mil.
How does Unity Biotechnology's Ending Cash Position compare to ADTX and HEPA?
Unity Biotechnology's Ending Cash Position of $8.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Unity Biotechnology and its competitors. Unity Biotechnology's current Ending Cash Position is $8.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (UNBX) has a current Ending Cash Position of $8.90 Mil. The current Ending Cash Position is $8.90 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Unity Biotechnology (UNBX), the current Ending Cash Position is $8.90 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.